Species : |
Human |
Source : |
Sf9 Cells |
Tag : |
Flag |
Description : |
The PI3K comprises of a 110 kDa catalytic subunit and a 85 kDa regulatory subunit. A number of isoforms of the 110 kDa catalytic subunit and the 85 kDa regulatory subunit exist in cells. The p110β catalytic subunit (PIK3CB) plays a role in regulating the formation and stability of alpha-2B-beta-3 integrin adhesion bonds, which are necessary for shear force-induced platelet activation. In animal model of prostate tumor formation induced by the tumor suppressor PTEN loss, ablation of p110β impedes tumorigenesis with a concomitant diminution of AKT phosphorylation. |
Formulated In : |
25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.05% Tween-20, 30% glycerol, and 3 mM DTT. |
Specific Activity : |
100 pmole/min/ug. A unit of 110β/p85α kinase activity is defined as the amount of enzyme required to produce 1 pmol of Phosphoinositol-3,4,5-Trisphosphate/min at 30°C. A 25μl kinase reaction is conducted in a buffer containing 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 100 μM ATP, 10μg mix of PS and Phosphoinositol-4,5-Bisphosphate, and 50 ng enzyme for 15 minutes at 30°C. Conversion of ATP to ADP is detected using PI3K ADP-Glo® Luminescent Kinase Assay (Promega Corporation, Madison, WI). |
Application : |
Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling. |
Stability : |
>6 months at –80°C. |
Pathways : |
Acute myeloid leukemia; Apoptosis; B cell receptor signaling pathway; Chemokine signaling pathway; Chronic myeloid leukemia; Colorectal cancer; Endometrial cancer; ErbB signaling pathway; Fc epsilon RI signaling pathway; Fc gamma R-mediated phagocytosis; Focal adhesion; Glioma; Inositol phosphate metabolism; Insulin signaling pathway; Jak-STAT signaling pathway; Leukocyte transendothelial migration; Melanoma; Natural killer cell mediated cytotoxicity; Neurotrophin signaling pathway; Non-small cell lung cancer; Pancreatic cancer; Pathways in cancer; Phosphatidylinositol signaling; Progesterone-mediated oocyte maturation; Prostate cancer; Regulation of actin cytoskeleton; Renal cell carcinoma; Small cell lung cancer; T cell receptor signaling pathway; Toll-like receptor signaling pathway; Type II diabetes mellitus; VEGF signaling pathway; mTOR signaling pathway |